Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Postgraduate School opens at UFS
2011-05-19

 
Prof. Maresi Nerad, from Washington university in Seattle, USA
Photo: Stephen Collett

We are celebrating the launch of our new Postgraduate School (PGS) on our Main Campus in Bloemfontein from 16 - 20 May 2011.

In line with national priorities for research-based postgraduate education and the focus of the UFS Academic Turnaround Strategy, the aims of the Postgraduate School are to:

  • improve the quality of postgraduate student research;
  • produce graduates who are global citizens, research literate and able to reflect ethically on the purpose, process and product of research;
  • improve throughput rates of postgraduate students; and
  • make the experience of being a postgraduate at the UFS one which is stimulating, enjoyable and which contributes to the development of the person beyond the limits of her or his discipline(s).

“We hope that the school will be a pleasant place to pursue research scholarship, discuss ideas and relax, and we look forward to welcoming postgraduates and other scholars to the school,” Prof. Neil Roos, Director of the UFS Postgraduate School said.

This significant event in the academic transformation of the university goes hand in hand with the inaugural lecture of Prof. Maresi Nerad. Prof. Nerad’s impressive CV reads amongst others that she has a M.A. (Political Science) at the Technical University of Darmstadt, Germany and a Ph.D. (Higher Education) at the University of California, Berkeley. She is also the founding director of the national Center for Innovation and Research Graduate Education (CIRGE).

As Professor Extraordinary in the UFS’s Postgraduate School, she is bringing more to the table than a world of wisdom and her passion for the postgraduate education. “I can contribute lessons learned from four distinct professional experiences, including 17 years of administrative and scholarly leadership in undertaking the conceptual and practical transformational work of organisational change at two US postgraduate schools, where I worked amongst others to improve the quality of mentoring, shorten the time to doctoral degree, and improve doctoral completion rates.”

She also brings to the UFS her experience as founding and current director of the first research center for studies on graduate education in the world. “It is our mission to discover how best to prepare Ph.D. students to be effective leaders in research and society,” she said.

Prof. Nerad says that she is committed to support and consult with the UFS Postgraduate School. She would particularly encourage the use of research to understand postgraduate education in all its dimensions at the UFS better and to use the evidence-based findings as a base for policy-making and resource allocation.

In reflecting on her vision for the UFS Postgraduate School, Prof. Nerad says that five years from now she hopes to see the UFS having strengthened its position as a major driving force in the national South African postgraduate-education community for internationalising postgraduate education. She is also confident that the UFS will supply increased numbers of skilled postgraduates who are “intellectual entrepreneurs and risk takers with a social consciousness, who have sustainability of the systems of the planet as a core value”.

“Five years from now the PSG will have taken the lead in preparing graduate students who are world citizens,” Prof. Nerad concluded.

 

Presentation on PhD students reveals more than meets the eye

British professor presents a discussion at UFS

Journey from student to scholar

Society will take care of interests

Female academics talk about joys and lessons

Research plus the internet equals the cyber scholar
 


 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept